Episode Details
Back to Episodes
In the News...Top Stories from ADA and more!
Description
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: loads of news from American Diabetes Association Scientific Sessions, GLP1 for T1D, Tech updates, diabetes in space, and more!
Find out more about Moms' Night Out
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
Check out VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Episode transcription with links:
Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.
XX
Top story – looking back at The American Diabetes Association Scientific Sessions conference. I won't recap everything here – but I'll link up to a few more comprehensive article. Here's just a taste!
XX
A single infusion of a new stem cell-based treatment helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report.
The treatment, called zimislecel, was made by Vertex Pharmaceuticals. It's an infusion of lab-grown islet cells. A year after getting the therapy, 10 patients no longer needed insulin shots. The other two were able to reduce how much insulin they needed. The treatment requires patients to take immunosuppressive drugs, which may raise the risk of infections or cancer in the long run, experts said.
https://www.usnews.com/news/health-news/articles/2025-06-24/stem-cell-treatment-may-free-some-with-type-1-diabetes-from-insulin
XX
New study shows inhaled insulin is safe and effective for children with type 1 diabetes. This is Mannkind's Afrezza, which takes the place of rapid-acting mealtime insulin.
Findings indicate that inhaled insulin delivers glycemic control comparable to injected rapid-acting insulin. Inhaled insulin was also associated with less weight gain and slightly